Frequency of CD40‐1C>T polymorphism (rs1883832) and association with response to treatment in children with primary immune thrombocytopenia

Heba A. Ahmed,Elsayed Abdelkreem,Elham O. Hamed,Nagwa M. Abo Elmahassen,Mustafa Adel A. Younis
DOI: https://doi.org/10.1002/pbc.31356
2024-10-02
Pediatric Blood & Cancer
Abstract:Objectives: To investigate whether (cluster of differentiation) CD40‐1C>T (rs1883832) contributes to predisposition and treatment response of primary immune thrombocytopenia (pITP) in children. Methods: A case–control study that included 100 children with newly diagnosed pITP and 50 age‐ and sex‐matched healthy controls. CD40 rs1883832 was genotyped using TaqMan allele discrimination real‐time polymerase chain reaction (PCR). Patients were categorized into responders and non‐responders according to their response to corticosteroids and thrombopoietin‐receptor agonists (TPO‐RA) at 3‐month intervals. Results: The genotypic distribution of the CD40 rs1883832 was significantly different among cases and controls (CC 48% vs. 30%; CT 44% vs. 42%; TT 8% vs. 28%; p = .003). Compared with controls, children with newly diagnosed pITP had significantly higher C allele frequency (70% vs. 51%; odds ratio [OR] 2.2, 95% confidence interval [CI]: 1.3–3.8; p = .001). The association between C allele frequency and pITP risk was evident in females (OR 4.3, 95% CI: 2.1–8.8; p
oncology,pediatrics,hematology
What problem does this paper attempt to address?